Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3314972 | Journal of Hepatology | 2006 | 5 Pages |
Abstract
In the largest cohort study to date, pegylated interferon-α therapy showed marginal efficacy in the presence of lamivudine resistance but such therapy may be beneficial in patients with only small amounts of mutant virus. In our opinion, an analysis of the patient subgroup harbouring an YMDD-mutation should be included in all future studies of pegylated interferon-α in chronic hepatitis B.
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Wilhelmus F. Leemans, Hajo J. Flink, Harry L.A. Janssen, Hubert G.M. Niesters, Solko W. Schalm, Robert A. de Man,